BC Week In Review | Mar 3, 2017
Company News

National Research Council Canada, Helix deal

NRC granted Helix worldwide rights to compound 2A3 for cancer indications. The license grants Helix the right to use the antibody in multiple systems, including CAR T cells , in combination with conjugates of the biotech's...
Items per page:
1 - 1 of 1